{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:34:41Z","timestamp":1789929281464,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40258-013-0050-0","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T08:54:22Z","timestamp":1377075262000},"page":"509-521","source":"Crossref","is-referenced-by-count":26,"title":["Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany"],"prefix":"10.1007","volume":"11","author":[{"given":"Jan","family":"Zeidler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"key":"50_CR1","volume-title":"Gesundheitsberichterstattung des Bundes: Heft 50\u2014Schizophrenie (The Federal Health Monitoring System: issue 50\u2014schizophrenia)","author":"Robert Koch-Institut","year":"2010","unstructured":"Robert Koch-Institut. Gesundheitsberichterstattung des Bundes: Heft 50\u2014Schizophrenie (The Federal Health Monitoring System: issue 50\u2014schizophrenia). Berlin: Robert Koch-Institut; 2010."},{"issue":"11","key":"50_CR2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-2007-995290","volume":"66","author":"W R\u00f6ssler","year":"1998","unstructured":"R\u00f6ssler W, Salize J, Knapp M. Die Kosten der Schizophrenie (The costs of schizophrenia). Fortschr Neurol Psychiatr. 1998;66(11):496\u2013504.","journal-title":"Fortschr Neurol Psychiatr"},{"key":"50_CR3","unstructured":"Statistisches Bundesamt. Krankheitskostenrechnung (Cost of illness) [online]. https:\/\/www.gbe-bund.de (Accessed 4 Dec 2012)."},{"key":"50_CR4","first-page":"81","volume":"3","author":"JM Schulenburg Von der","year":"1998","unstructured":"Von der Schulenburg JM, Uber A, H\u00f6ffler J, et al. Untersuchungen zu den direkten und indirekten Kosten der Schizophrenie (Studies on direct and indirect costs of schizophrenia). Gesundheits\u00f6konomie & Qualit\u00e4tsmanagement. 1998;3:81\u20137.","journal-title":"Gesundheits\u00f6konomie & Qualit\u00e4tsmanagement"},{"issue":"1","key":"50_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-993735","volume":"67","author":"W Kissling","year":"1999","unstructured":"Kissling W, H\u00f6ffler J, Seemann U, et al. Die direkten und indirekten Kosten der Schizophrenie (Direct and indirect costs of schizophrenia). Fortschr Neurol Psychiatr. 1999;67(1):29\u201336.","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"2","key":"50_CR6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-2001-13024","volume":"6","author":"C Roick","year":"2001","unstructured":"Roick C, Killian R, Reinhold K, et al. Die indirekten Kosten schizophrener Psychosen (Indirect costs of schizophrenia). Gesundheits\u00f6konomie & Qualit\u00e4tsmanagement. 2001;6(2):36\u201343.","journal-title":"Gesundheits\u00f6konomie & Qualit\u00e4tsmanagement"},{"issue":"5","key":"50_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0028-1090234","volume":"36","author":"A Konnopka","year":"2009","unstructured":"Konnopka A, Klingberg S, Wittorf A, et al. Die Kosten der Schizophrenie in Deutschland: Ein systematischer Literatur\u00fcberblick (The cost of schizophrenia in Germany: a systematic review of the literature). Psychiatr Prax. 2009;36(5):211\u20138.","journal-title":"Psychiatr Prax"},{"issue":"30","key":"50_CR8","first-page":"A10532","volume":"105","author":"J Klosterk\u00f6tter","year":"2008","unstructured":"Klosterk\u00f6tter J. Indizierte Pr\u00e4vention schizophrener Erkrankungen (Indicated prevention of schizophrenia). Dtsch Arztebl. 2008;105(30):A10532.","journal-title":"Dtsch Arztebl"},{"issue":"Suppl. 2","key":"50_CR9","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1055\/s-2001-17793","volume":"28","author":"R Kilian","year":"2001","unstructured":"Kilian R, Roick C, Matschinger H, et al. Die Analyse von Kostenstrukturen im Bereich der Schizophreniebehandlung mit einem standardisierten Instrumentarium (The analysis of the cost structures of the treatment of schizophrenia by means of standardized assessment instruments). Psychiatr Prax. 2001;28(Suppl. 2):S102\u20138.","journal-title":"Psychiatr Prax"},{"key":"50_CR10","unstructured":"Salize HJ, R\u00f6ssler W, Reinhard I. Kostenermittlung in einem fragmentierten psychiatrischen Versorgungssystem (Cost assessment in a fragmented psychiatric treatment system). Gesundheitswesen. 1996;Suppl. 1:10\u20137."},{"issue":"1","key":"50_CR11","first-page":"38","volume":"25","author":"M Osterheider","year":"1998","unstructured":"Osterheider M, Franken-Hiep K, Horn R. Gesamtkrankenkosten der Schizophrenie und monet\u00e4re Bewertung einer Rezidivprophylaxe am Beispiel eines Standard-Depot-Neuroleptikums (Flupentixoldecanoat) (Total illness costs of schizophrenia and monetary evaluation of prevention of recurrence exemplified by a standard depot neuroleptic (flupenthixol decanoate)). Psychiatr Prax. 1998;25(1):38\u201343.","journal-title":"Psychiatr Prax"},{"issue":"7","key":"50_CR12","doi-asserted-by":"crossref","first-page":"A449","DOI":"10.1016\/S1098-3015(11)72897-2","volume":"13","author":"J Zeidler","year":"2010","unstructured":"Zeidler J, Slawik L, Fleischmann J, et al. Impact and costs of hospitalisation in schizophrenia [abstract]. Value Health. 2010;13(7):A449.","journal-title":"Value Health"},{"issue":"5","key":"50_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/00048670801961107","volume":"42","author":"C Rummel-Kluge","year":"2008","unstructured":"Rummel-Kluge C, Schuster T, Peters S, et al. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry. 2008;42(5):382\u20138.","journal-title":"Aust N Z J Psychiatry"},{"issue":"Suppl. 16","key":"50_CR14","first-page":"3","volume":"64","author":"SR Marder","year":"2003","unstructured":"Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003;64(Suppl. 16):3\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"50_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2008.09.007","volume":"107","author":"FJ Acosta","year":"2009","unstructured":"Acosta FJ, Bosch E, Sarmiento G, et al. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res. 2009;107(2):213\u20137.","journal-title":"Schizophr Res"},{"issue":"6","key":"50_CR16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10198-009-0215-9","volume":"11","author":"M Willis","year":"2010","unstructured":"Willis M, Svensson M, L\u00f6thgren M, et al. The impact of schizophrenia-related hospital utilization and cost of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585\u201394.","journal-title":"Eur J Health Econ"},{"issue":"6","key":"50_CR17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603\u20139.","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"50_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2011.10.022","volume":"134","author":"L Grimaldi-Bensouda","year":"2012","unstructured":"Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134(2\u20133):187\u201394.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"50_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","volume":"127","author":"C Leucht","year":"2011","unstructured":"Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1\u20133):83\u201392.","journal-title":"Schizophr Res"},{"issue":"5","key":"50_CR20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","volume":"24","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287\u201396.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"50_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00148365-200806010-00004","volume":"6","author":"JM Olivares","year":"2008","unstructured":"Olivares JM, Rodriguez-Martinez A, Bur\u00f3n JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to longacting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41\u201353.","journal-title":"Appl Health Econ Health Policy"},{"issue":"12","key":"50_CR22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","volume":"35","author":"W Gaebel","year":"2010","unstructured":"Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label. Randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367\u201377.","journal-title":"Neuropsychopharmacology"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13651500903311821","volume":"14","author":"B Spill","year":"2010","unstructured":"Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14:53\u201362.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"Suppl. 1","key":"50_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00019053-200523001-00005","volume":"23","author":"G Laux","year":"2005","unstructured":"Laux G, Heeg B, van Hout B, et al. Costs and effects or long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. PharmacoEconomics. 2005;23(Suppl. 1):49\u201361.","journal-title":"PharmacoEconomics"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1744-859X-11-18","volume":"11","author":"T Einarson","year":"2012","unstructured":"Einarson T, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11:18.","journal-title":"Ann Gen Psychiatry"},{"key":"50_CR26","author":"T Einarson","year":"2012","unstructured":"Einarson T, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr. 2012. doi: 10.1111\/j.1601-5215.2012.00670.x .","journal-title":"Acta Neuropsychiatr"},{"issue":"5","key":"50_CR27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3111\/13696998.2012.681531","volume":"15","author":"A Mehnert","year":"2012","unstructured":"Mehnert A, Nicholl D, Pudas H, et al. Cost-effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Schweden. J Med Econ. 2012;15(5):844\u201361.","journal-title":"J Med Econ"},{"issue":"7","key":"50_CR28","doi-asserted-by":"crossref","first-page":"A294","DOI":"10.1016\/j.jval.2011.08.341","volume":"14","author":"B Kim","year":"2011","unstructured":"Kim B, Lee TJ, Woo JM, et al. Cost-utility analysis of paliperidone Palmitat long acting injection (PLAI) vs oral atypical antipsychotics in non-adherent schizophrenia patients. Value Health. 2011;14(7):A294.","journal-title":"Value Health"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1524-4733.2007.00214.x","volume":"11","author":"J Ahn","year":"2008","unstructured":"Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health. 2008;11:48\u201356.","journal-title":"Value Health"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","volume":"115","author":"HA Nasrallah","year":"2007","unstructured":"Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260\u20137.","journal-title":"Acta Psychiatr Scand"},{"key":"50_CR31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.571","volume":"19","author":"K Sim","year":"2004","unstructured":"Sim K, Su A, Ungvari GS, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol. 2004;19:103\u20139.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"50_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2012.667465","volume":"15","author":"NC Edwards","year":"2012","unstructured":"Edwards NC, Muser E, Doshi D, et al. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone Palmitat is cost saving. J Med Econ. 2012;15(4):1\u201312.","journal-title":"J Med Econ"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","volume":"6","author":"A Briggs","year":"2008","unstructured":"Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.","journal-title":"Health Qual Life Outcomes"},{"key":"50_CR34","unstructured":"Lauer-Fischer GmbH. Lauer-Taxe [online]. http:\/\/taxe.lauer-fischer.de\/Taxe\/taxe.aspx (Accessed 4 Dec 2012)."},{"key":"50_CR35","unstructured":"Prenzler A, Zeidler J, Braun S, et al. Bewertung von Ressourcen im Gesundheitswesen aus der Perspektive der deutschen Sozialversicherung (Assessment of health care resources from the viewpoint of the German social insurance system). PharmacoEconomics. 2010;8(1):47\u201366."},{"key":"50_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0028-1102930","volume":"71","author":"S Braun","year":"2009","unstructured":"Braun S, Prenzler A, Mittendorf T, et al. Bewertung von Ressourcenverbr\u00e4uchen im deutschen Gesundheitswesen aus Sicht der Gesetzlichen Krankenversicherung (Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance). Gesundheitswesen. 2009;71:19\u201323.","journal-title":"Gesundheitswesen"},{"key":"50_CR37","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Adressliste der Kassen\u00e4rztlichen Vereinigungen (Adress list of the Associations of Statutory Health Insurance Physicians) [online]. http:\/\/www.kbv.de\/wir_ueber_uns\/4130.html#Kassen%C3%A4rztliche%20Vereinigung%20Baden-W%C3%BCrttemberg (Accessed 4 Dec 2012)."},{"key":"50_CR38","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerung nach Bundesl\u00e4ndern (Population in federal states) [online]. https:\/\/www-genesis.destatis.de\/genesis\/online\/link\/tabelleErgebnis\/12411-0021 ."},{"key":"50_CR39","doi-asserted-by":"crossref","unstructured":"Schneider F, Falkai P, Maier W. Psychiatrie 2020 plus (Psychiatry 2020 plus) [online]. http:\/\/www.springerlink.com\/content\/n14116\/#section=1081192&page=1 (Accessed 4 Dec 2012).","DOI":"10.1007\/978-3-642-28221-8_1"},{"key":"50_CR40","unstructured":"Braun S, Zeidler J, Mittendorf T, et al. Kosteneffektivit\u00e4t von Quetiapin und Haloperidol bei Patienten mit partiell therapieresistenter Schizophrenie (Cost-effectiveness analysis of quetiapine and haloperidol for partial responders in schizophrenia). PharmacoEconomics. 2010;8(1):21\u20139."},{"key":"50_CR41","unstructured":"Statistisches Bundesamt. Verbraucherpreisindex (Consumer price index) [online]. https:\/\/www-genesis.destatis.de ."},{"key":"50_CR42","unstructured":"Kassen\u00e4rztliche Vereinigung Westfalen-Lippe. Heilmittel-Einzelpreise (remedy price list) [online]. http:\/\/www.kvwl.de\/arzt\/verordnung\/hhm\/heilmittel\/preise.htm (Accessed 4 Dec 2012)."},{"key":"50_CR43","unstructured":"Melchinger H. Strukturfragen der ambulanten psychiatrischen Versorgung (Structure of outpatient psychiatric care) [online]. http:\/\/www.google.de\/url?sa=t&rct=j&q=melchinger%20h&source=web&cd=8&ved=0CE8QFjAH&url=http%3A%2F%2Fwww.root.webdestination.de%2Fkunden%2F01extern%2Fbdn_redaktion_ssl_neu%2Fupload%2Fkbv_gutachten_%28endfassung_%29.pdf&ei=JHpYULnABYbRtAbAy4HACg&usg=AFQjCNG3y_U892zHAaw9Aro4qQ_Vv-j3IA&cad=rja (Accessed 4 Dec 2012)."},{"key":"50_CR44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-2007-995225","volume":"67","author":"M Bestehorn","year":"1999","unstructured":"Bestehorn M, Tischer B, Glaser P, et al. Repr\u00e4sentative Studie zur Verteilung schizophrener Patienten auf medizinische Versorgungseinrichtungen in Deutschland (Representative Study on the Distribution of Schizophrenia Patients to Medical Health Care Institutions in Germany). Fortschr Neurol Psychiatr Grenzgeb. 1999;67:487\u201392.","journal-title":"Fortschr Neurol Psychiatr Grenzgeb"},{"key":"50_CR45","first-page":"181","volume-title":"Krankenhaus-Report 2010","author":"J Fritze","year":"2009","unstructured":"Fritze J. Entgeltsystem f\u00fcr psychiatrische und psychosomatische Einrichtungen (Remuneration System for psychiatric and psychosomatic facilities). In: Klauber J, Geraedts M, Friedrich J, editors. Krankenhaus-Report 2010. Stuttgart: Schattauer; 2009. p. 181\u2013208."},{"key":"50_CR46","unstructured":"Statistisches Bundesamt. Diagnosedaten der Krankenh\u00e4user (Diagnostic data of the hospitals) [online]. http:\/\/www.gbe-bund.de (Accessed 4 Dec 2012)."},{"issue":"5","key":"50_CR47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.pnpbp.2009.03.034","volume":"33","author":"J Hong","year":"2009","unstructured":"Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Progr Neuropsychopharmacol Biol Psychiatry. 2009;33(5):835\u201341.","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 9","key":"50_CR48","first-page":"5","volume":"57","author":"JA Lieberman","year":"1996","unstructured":"Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 9):5\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"50_CR49","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2003-815030","volume":"32","author":"M Sch\u00fctzwohl","year":"2005","unstructured":"Sch\u00fctzwohl M, Gl\u00f6ckner M, Matthes C, et al. The burden on relatives of acute mentally ill within the first four weeks of day hospital and inpatient treatment. Results from a randomized controlled trial. Psychiatr Prax. 2005;32(6):281\u20138.","journal-title":"Psychiatr Prax"},{"issue":"7","key":"50_CR50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-2006-940120","volume":"33","author":"R Schmid","year":"2006","unstructured":"Schmid R, Neuner T, Cording C, et al. Schizophrenic patients\u2019 quality of life-association with coping, locus of control, subjective well-being, satisfaction and patient-judged caregiver burden. Psychiatr Prax. 2006;33(7):337\u201343.","journal-title":"Psychiatr Prax"},{"issue":"1","key":"50_CR51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","volume":"138","author":"R Emsley","year":"2012","unstructured":"Emsley R, Nuamah I, Hough D, et al. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138(1):29\u201334.","journal-title":"Schizophr Res"},{"issue":"5","key":"50_CR52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","volume":"22","author":"S Heres","year":"2007","unstructured":"Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275\u201382.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"50_CR53","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0269881109103133","volume":"24","author":"MX Patel","year":"2010","unstructured":"Patel MX, de Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? The patient\u2019s perspective. J Psychopharmacol. 2010;24(10):1483\u20139.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"50_CR54","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0269881108092124","volume":"23","author":"MX Patel","year":"2009","unstructured":"Patel MX, De Zoysa N, Bernadt M, et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009;23(7):789\u201396.","journal-title":"J Psychopharmacol"},{"key":"50_CR55","author":"S Frey","year":"2013","unstructured":"Frey S, Linder R, Juckel G, et al. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. Eur J Health Econ. 2013. doi: 10.1007\/s10198-013-0460-9 .","journal-title":"Eur J Health Econ"},{"issue":"5","key":"50_CR56","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/JCP.0b013e318268ddc0","volume":"32","author":"T Stargardt","year":"2012","unstructured":"Stargardt T, Edel MA, Ebert A, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany. J Clin Psychopharmacol. 2012;32(5):602\u20137.","journal-title":"J Clin Psychopharmacol"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-013-0050-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0050-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T15:09:32Z","timestamp":1563721772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-013-0050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s40258-013-0050-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]}}}